[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352974-105":59,"doc-detail-352974-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clinical-outcomes-of-cyberknife-stereotactic-radiotherapy-for-localized-prostate-cancer-comparison-of-35-gy-in-5-fractions-and-36-gy-in-4-fractions","Clinical outcomes of CyberKnife stereotactic radiotherapy for localized prostate cancer - comparison of 35 Gy in 5 fractions and 36 Gy in 4 fractions","","This retrospective study evaluated the clinical outcomes of two CyberKnife (CK) stereotactic body radiation therapy (SBRT) regimens for patients with localized prostate cancer. A total of 249 men were treated, with 123 receiving 35 Gy in 5 fractions and 126 receiving 36 Gy in 4 fractions, with a median follow-up of 50 months. The primary endpoint assessed grade ≥2 genitourinary and gastrointestinal toxicities using CTCAE v5.0, with inverse probability of treatment weighting applied to address baseline imbalances. After adjustment, 3-year biochemical recurrence-free survival was 96.5% vs 96.8%, and locoregional recurrence-free survival was 99.2% vs 100% between groups, while distant metastasis-free survival was 100% vs 97.5% (P=0.058). CK-SBRT with 36 Gy in 4 fractions showed low toxicity rates and no statistically significant differences in oncologic outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-outcomes-of-cyberknife-stereotactic-radiotherapy-for-localized-prostate-cancer-comparison-of-35-gy-in-5-fractions-and-36-gy-in-4-fractions/352974/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-outcomes-of-cyberknife-stereotactic-radiotherapy-for-localized-prostate-cancer-comparison-of-35-gy-in-5-fractions-and-36-gy-in-4-fractions/352974.png","ImageObject",300,407,{"name":92,"@type":93},"Adam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How many patients were included and what treatment regimens were compared?","Question",{"text":112,"@type":113},"A total of 249 patients were treated. The study compared 35 Gy in 5 fractions versus 36 Gy in 4 fractions using CyberKnife SBRT.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What was the primary endpoint of the study?",{"text":117,"@type":113},"The primary endpoint was the incidence of grade ≥2 genitourinary and gastrointestinal toxicities, assessed with CTCAE Version 5.0.",{"name":119,"@type":110,"acceptedAnswer":120},"Did dose fractionation affect oncologic outcomes such as biochemical recurrence-free survival?",{"text":121,"@type":113},"After inverse probability of treatment weighting, the 3-year biochemical recurrence-free survival was 96.5% for the 5-fraction group and 96.8% for the 4-fraction group (P=0.571), showing no statistically significant difference.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352974,1790182511,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1374404737137,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Journal of Radiation Research, Vol. 67, No. 3, 2026, pp. 402–411 [https://doi.org/10.1093/jrr/rrag017](https://doi.org/10.1093/jrr/rrag017)  \nAdvance Access Publication: 14 April 2026  \nClinical outcomes of CyberKnife stereotactic radiotherapy for localized prostate cancer:  \ncomparison of 35 Gyin 5 fractions and 36 Gy  \nin 4 fractions  \nJiyoon Lim1,†, Yoon Y.Jo2,†, Sumin Lee3, *  andYeon J. Kim 1, *   \n1Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea  \n2Department of Radiation Oncology, Yeungnam University Medical Center, 170 Hyeonchung-ro, Nam-gu, Daegu 42415, South Korea  \n3Department of Radiation Oncology, Kangwon National University Hospital, 156 Baengnyeong-ro, Chuncheon-si, Gangwon-do 24289, South Korea  \n*Corresponding author. Yeon J. Kim, Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea. Tel: +82-2-3010-5617; Fax: +82-2-3010-6950; [Email: kamea1004@naver.com. Sumin Lee](Email: kamea1004@naver.com. Sumin Lee), Department of Radiation Oncology, Kangwon National University Hospital, 156 Baengnyeong-ro, Chuncheon-si, Gangwon-do 24289, Republic of Korea. Tel.: +82-10-6554-7545;  \nFax: +82-33-258-9472; Email: [ls4011@naver.com](ls4011@naver.com).  \n†Jiyoon Lim and Yoon Y.Jo contributed equally to this work as co-first authors.  \n(Received 14 October 2025; revised 30 December 2025; accepted 24 February 2026)  \nABSTRACT  \nThis retrospective study evaluated the clinical outcomes of two CyberKnife (CK) stereotactic body radiation therapy (SBRT) regimens in patients with localized prostate cancer (LPC). A total of 249 patients were treated, with 123 receiving 35 Gy in 5 fractions and 126 receiving 36 Gy in 4 fractions, with a median follow-up of 50 months. The primary endpoint was the incidence of grade ≥2 genitourinary (GU) and gastrointestinal (GI) toxicities, assessed using CTCAE Version 5.0. Secondary endpoints included 3-year biochemical recurrence-free survival (BCRFS), locoregional recurrence-free survival (LRRFS) and distant metastasis-free survival (DMFS). To address baseline imbalances between groups, inverse probability of treatment weighting (IPTW) was applied. Acute grade 2 GUtoxicities occurred in 19 patients (7.6%) and chronic grade 2 in 15 patients (6.0%). Acute and chronic grade 2 GI toxicities were rare, occurring in 3 (1.2%) and 2 (0.8%) patients, respectively. There were no significant differences in cumulative GU or GI toxicity rates between fractionation regimens either before or after IPTW adjustment. After IPTW, the 3-year BCRFS was 96.5% in the 5-fraction group and 96.8% in the 4-fraction groups (P= 0.571). The 3-year LRRFS rates were similarly favorable (99.2% vs. 100%). The 3-year DMFS was 100% in the 5-fraction group and 97.5% in the 4-fraction group (P= 0.058). Overall, CK-SBRT using 36 Gyin 4 fractions was well tolerated, with low rates of treatment-related toxicity and no statistically significant differences in oncologic outcomes between regimens.  \nLonger follow-up is required to determine the long-term efficacy of this dose-escalation strategy.  \nKeywords: CyberKnife; stereotactic body radiation therapy; prostate cancer; dose escalation; toxicity  \nINTRODUCTION  \nProstate cancer is the most commonly diagnosed cancer among men in the United States, with 288 300 new cases reported in 2023, ∼70% of which were detected at a localized stage [ 1]. Due to the typically slow progression of prostate cancer, current guidelines recommend a risk-stratified management approach that considers the clinical stage, pathologic grade and patient life expectancy [2–4]. A variety of treatment options are available for managing localized prostate cancer (LPC), including active surveillance, radical prostatectomy and radiation therapy, all of which have reported 10-year overall survival rates of 100%[5].  \nRadi","cbCainZw30z8TqpF","https://ap.wps.com/l/cbCainZw30z8TqpF","pdf",856652,"English","# Abstract\n# Introduction\n## Guideline-based management of localized prostate cancer\n## Rationale for hypofractionation and dose escalation\n## Role of CyberKnife stereotactic body radiation therapy","[{\"question\":\"How many patients were included and what treatment regimens were compared?\",\"answer\":\"A total of 249 patients were treated. The study compared 35 Gy in 5 fractions versus 36 Gy in 4 fractions using CyberKnife SBRT.\"},{\"question\":\"What was the primary endpoint of the study?\",\"answer\":\"The primary endpoint was the incidence of grade ≥2 genitourinary and gastrointestinal toxicities, assessed with CTCAE Version 5.0.\"},{\"question\":\"Did dose fractionation affect oncologic outcomes such as biochemical recurrence-free survival?\",\"answer\":\"After inverse probability of treatment weighting, the 3-year biochemical recurrence-free survival was 96.5% for the 5-fraction group and 96.8% for the 4-fraction group (P=0.571), showing no statistically significant difference.\"}]","Clinical outcomes of CyberKnife stereotactic radiotherapy for localized prostate cancer - comparison of 35 Gy in 5 fractions and 36 Gy in 4 fractions | PDF",1790102362,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d891d5d042286302fbbe4df1aeef29bb.webp",983,1269,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f4b5b67a203baca13a82311af53b0ba.webp",982,1268,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7819f70fded24c66e693ca8b43640154.webp",981,1266,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0fcc91183d2b7aeec544247528f254bd.webp",980,1265]